AstraZeneca Pharma India Limited (ASTRAZEN.NS)
AstraZeneca Pharma India Limited operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Bengaluru, KA, IN. The stock last traded at $7753.00, down 0.51% on the session, giving a market capitalisation of $193.82B. Its beta of 0.25 implies it has historically moved less than the broad market.
AstraZeneca Pharma India Limited operates as a biopharmaceutical entity, engaged in the development, production, and global commercialization of pharmaceutical products, serving both the Indian domestic market and international clientele. The company offers an extensive range of medications, including treatments for cardiovascular conditions and diabetes, marketed under brands such as Brilinta, Betaloc, Crestor, Forxiga, Imdur, Kombiglyze XR, Onglyza, Seloken XL, Xigduo XR, and QTERN. Its respiratory portfolio features products like Symbicort and FASENRA, while its oncology division provides various cancer therapies, including LYNPARZA, Tagrisso, Iressa, Calquence, Casodex, Faslodex, Zoladex, and Arimidex. Furthermore, the firm extends its product line to encompass therapeutic solutions for renal, metabolic, and immunological disorders. Beyond its pharmaceutical offerings, AstraZeneca Pharma India Limited also provides clinical trial services. Established in 1979, the company is based in Bengaluru, India, and functions as a subsidiary of AstraZeneca Pharmaceuticals AB.
AstraZeneca Pharma India Limited is most often compared with the following Healthcare names: